1. Eli Lilly, Loxo Oncology. Lilly completes acquisition of Loxo Oncology
[media release]. 15 Feb 2019. http://www.lilly.com.
2. Subbiah V, Yang D, Velcheti V, et al. State-of-the-Art strategies for
targeting RET-dependent cancers. J Clin Oncol. 2020;38(11):1209–21.
3. US Food & Drug Administration. FDA approves selpercatinib for lung
and thyroid cancers with RET gene mutations or fusions. Media Release.
2020.
4. Eli Lilly. RETEVMOTM (selpercatinib): US
prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Accessed 2020.
5. Pfizer. Pfizer completes acquisition of Array Biopharma [media
release]. 30 Jul 2019. http://www.pfizer.com.